Translational control of ERK signaling through miRNA/4EHP-directed silencing by Jafarnejad, Seyed Mehdi et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Translational control of ERK signaling through miRNA/4EHP-
directed silencing
Citation for published version:
Jafarnejad, SM, Chapat, C, Matta-Camacho, E, Gelbart, IA, Hesketh, GG, Arguello, M, Garzia, A, Kim, S,
Attig, J, Shapiro, M, Morita, M, Khoutorsky, A, Alain, T, Gkogkas, C, Stern-Ginossar, N, Tuschl, T, Gingras,
A-C, Duchaine, TF & Sonenberg, N 2018, 'Translational control of ERK signaling through miRNA/4EHP-
directed silencing', eLIFE. https://doi.org/10.7554/eLife.35034
Digital Object Identifier (DOI):
10.7554/eLife.35034
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
eLIFE
Publisher Rights Statement:
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted
use and redistribution provided that the original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 1 
Translational control of ERK signaling through miRNA/4EHP-directed 1 
silencing 2 
 3 
Seyed Mehdi Jafarnejad1,a,b, Clément Chapat1,a,b, Edna Matta-Camachoa,b, Idit A. 4 
Gelbartc, Geoffrey G. Heskethd, Meztli Arguelloa,b, Aitor Garziae, Sung-Hoon Kima,b, Jan 5 
Attigf, Maayan Shapiroa,b, Masahiro Moritaa,b,g, Arkady Khoutorskyh, Tommy Alaini, 6 
Christos G. Gkogkasj, Noam Stern-Ginossarc, Thomas Tuschle, Anne-Claude Gingrasd,k, 7 
Thomas Duchainea,b,2 and Nahum Sonenberg a,b,2 8 
1 These authors contributed equally to this manuscript 9 
a Goodman Cancer Research Center, McGill University, Montreal, QC H3A 1A3, Canada 10 
b
 Department of Biochemistry, McGill University, Montreal, QC H3A 1A3, Canada 11 
c The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel 12 
d Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health 13 
System, Toronto, Ontario, Canada 14 
e Howard Hughes Medical Institute and Laboratory for RNA Molecular Biology, The 15 
Rockefeller University, 1230 York Ave, Box 186, New York, NY 10065 16 
f The Francis Crick Institute, London, NW1 1AT, United Kingdom 17 
g Present address: Department of Molecular Medicine and Barshop Institute for Longevity 18 
and Aging Studies, University of Texas Health Science Center at San Antonio, San 19 
Antonio, TX 78229, USA 20 
h
 Department of Anesthesia and Alan Edwards Centre for Research on Pain, McGill 21 
University, H3A 0G1, Montréal, QC, Canada 22 
 2 
i Children’s Hospital of Eastern Ontario Research Institute, Department of Biochemistry, 23 
Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada 24 
j Patrick Wild Centre, Centre for Discovery Brain Sciences, University of Edinburgh, 25 
Edinburgh, EH8 9XD, UK 26 
k Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada 27 
 28 
 29 
2 Correspondence: nahum.sonenberg@mcgill.ca, thomas.duchaine@mcgill.ca 30 
Lead Contact: Nahum Sonenberg   nahum.sonenberg@mcgill.ca, 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 3 
ABSTRACT 41 
MicroRNAs (miRNAs) exert a broad influence over gene expression by directing effector 42 
activities that impinge on translation and stability of mRNAs. We recently discovered 43 
that the cap-binding protein 4EHP is a key component of the mammalian miRNA-44 
Induced Silencing Complex (miRISC), which mediates gene silencing. However, little is 45 
known about the mRNA repertoire that is controlled by the 4EHP/miRNA mechanism or 46 
its biological importance. Here, using ribosome profiling, we identify a subset of mRNAs 47 
that are translationally controlled by 4EHP. We show that the Dusp6 mRNA, which 48 
encodes an ERK1/2 phosphatase, is translationally repressed by 4EHP and a specific 49 
miRNA, miR-145. This promotes ERK1/2 phosphorylation, resulting in augmented cell 50 
growth and reduced apoptosis. Our findings thus empirically define the integral role of 51 
translational repression in miRNA-induced gene silencing and reveal a critical function 52 
for this process in the control of the ERK signalling cascade in mammalian cells.  53 
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INTRODUCTION 60 
mRNA translation commences with the binding of the eukaryotic initiation factor 4F 61 
(eIF4F) to the mRNA 5´ cap structure. eIF4F is a three-subunit complex composed of 62 
eIF4E, the m7GpppN (cap)-interacting factor; eIF4G, a scaffolding protein, and eIF4A, a 63 
DEAD-box RNA helicase (Sonenberg & Hinnebusch, 2009). eIF4G also interacts with 64 
eIF3, through which it recruits the pre-initiation complex, comprised of the 40S 65 
ribosomal subunit and associated factors, to the mRNA. Binding of the mRNA 5´ cap by 66 
the 4E Homologous Protein (4EHP, encoded by Eif4e2), in contrast to eIF4E, impairs 67 
translation initiation (Cho et al., 2005; Morita et al., 2012; Rom et al., 1998a). 4EHP 68 
shares 28% sequence identity with eIF4E (Rom et al., 1998b) and is ubiquitously 69 
expressed, although it is 5–10 times less abundant than eIF4E in most cell types (Joshi, 70 
Cameron, & Jagus, 2004). 4EHP binds the cap with 30- to 100-fold weaker affinity than 71 
eIF4E, but its affinity is increased by interactions with other proteins such as 4E-T or 72 
post-translational modification (Chapat et al., 2017; Okumura, Zou, & Zhang, 2007). 73 
4EHP is involved in translational repression directed by miRNAs (Chapat et al., 2017; 74 
Chen & Gao, 2017). The miRNA-Induced Silencing Complex (miRISC) recruits the 75 
CCR4–NOT complex to effect mRNA translational repression and decay (Jonas & 76 
Izaurralde, 2015). CCR4–NOT in turn recruits DDX6, 4E-T (eIF4E-Transporter; a 77 
conserved 4EHP/eIF4E-binding protein) and 4EHP to suppress cap-dependent mRNA 78 
translation (Chapat et al., 2017; Jonas & Izaurralde, 2015; Kamenska et al., 2014; 79 
Kamenska et al., 2016; Ozgur et al., 2015). However, which cellular mRNAs are targeted 80 
by 4EHP remains unknown. 81 
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The Extracellular signal-Regulated Kinases (ERK1/2) are important effectors of the 82 
highly conserved Mitogen-Activated Protein Kinase (MAPK) signalling pathways (Will 83 
et al., 2014). ERK signalling is controlled by the RAS GTPase, which activates RAF, a 84 
serine/threonine kinase. RAF phosphorylates and activates the kinase MEK, which in 85 
turn phosphorylates and activates the effector serine/threonine kinases ERK1/2. Activated 86 
ERK signalling elicits multiple outcomes, including transcriptional programs that control 87 
cellular functions such as cell proliferation (Aktas, Cai, & Cooper, 1997; Samatar & 88 
Poulikakos, 2014), apoptosis (Xia, Dickens, Raingeaud, Davis, & Greenberg, 1995) and 89 
mRNA translation (Fukunaga & Hunter, 1997). 90 
Dual specificity phosphatase 6 (DUSP6), also called MAP kinase phosphatase-3 (MKP-91 
3), is a highly specific phosphatase for ERK1/2 (Caunt & Keyse, 2013) and a key player 92 
in ERK signalling regulatory feedback loops (Camps et al., 1998; Eblaghie et al., 2003; 93 
Kolch, 2005; Mendoza, Er, & Blenis, 2011). Dusp6-/- mice exhibit increased ERK1/2 94 
phosphorylation at Thr202/Tyr204 residues (C. Y. Li, D. A. Scott, E. Hatch, X. Y. Tian, 95 
& S. L. Mansour, 2007). DUSP6 expression is regulated transcriptionally (Bermudez et 96 
al., 2011b; Ekerot et al., 2008; Zhang et al., 2010), and post-transcriptionally by miRNAs 97 
(Banzhaf-Strathmann et al., 2014; Carson et al., 2017; Y. Gu et al., 2015) and RNA-98 
binding proteins (Bermudez et al., 2011b; Galgano et al., 2008; Lee, Hook, Lamont, 99 
Wickens, & Kimble, 2006). Altered expression or activity of DUSP6 impacts on ERK 100 
signalling in various diseases such as cancer and neurological disorders (Banzhaf-101 
Strathmann et al., 2014; Bermudez, Marchetti, Pages, & Gimond, 2008; Kawakami et al., 102 
2003; C. Li, D. A. Scott, E. Hatch, X. Tian, & S. L. Mansour, 2007; Molina et al., 2009; 103 
Pfuhlmann et al., 2017; Shojaee et al., 2015).  104 
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Here, we employed ribosome profiling to identify a subset of mRNAs that are regulated 105 
by 4EHP. We discovered that Dusp6 mRNA translation is repressed by a 4EHP/miRNA-106 
dependent mechanism, which impacts on ERK1/2 phosphorylation, cell proliferation, and 107 
apoptosis. Our results underscore the biological importance of this translation repression 108 
mechanism, which is jointly orchestrated by miRNAs and 4EHP.  109 
RESULTS 110 
Enrichment for miRNA-binding sites in 4EHP-regulated mRNAs. 111 
We recently discovered that 4EHP acts as a key component of the translational repression 112 
machinery, which is mobilized by miRNAs (Chapat et al., 2017). To identify mRNAs 113 
that are translationally controlled by 4EHP, we carried out ribosome profiling (Ingolia, 114 
Lareau, & Weissman, 2011) in wild-type (WT) and 4EHP knockout (4EHP-KO) mouse 115 
embryonic fibroblasts (MEFs) (Fig. S1A and B). This assay measures the ribosome 116 
occupancy of each mRNA by deep sequencing of ribosome-protected mRNA fragments 117 
(ribosome footprints; RFPs) (Ingolia et al., 2011). We used the Babel tool (Olshen et al., 118 
2013; Stumpf, Moreno, Olshen, Taylor, & Ruggero, 2013) to detect significant changes 119 
in translation efficiency (abundance of RFPs independently of changes in the levels of 120 
their corresponding mRNAs). Translation was up-regulated for 117 mRNAs (hereafter 121 
referred to as upregulated mRNAs) in 4EHP-KO in comparison to WT cells, while 122 
translation was down-regulated for 167 mRNAs (Fig. 1A and Supplementary file 1). 123 
Whereas the translational up-regulation of the mRNAs can be explained by the activity of 124 
4EHP as translational suppressor, translational downregulation may be the result of 125 
indirect adaptation effects following 4EHP loss.  126 
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We next analyzed the upregulated  mRNAs for the presence of common sequence 127 
features in their UTRs or coding sequences. A significant positive correlation was 128 
observed between the length of the 3′ UTR and increased translation of the upregulated   129 
mRNAs in the 4EHP-KO cells (average of 2838.6, 2325.2, and 2016 nt for the up-130 
regulated, unchanged and down-regulated mRNAs, respectively; p-value < 2.2e-16; Fig. 131 
1B). We also found a less significant correlation (p= 1.742e-05; Fig. S1C) between the 132 
length of the 5´ UTR and increased mRNA translation efficiency in the 4EHP-KO cells. 133 
This indicates that mRNAs with longer 3´ UTR are more likely to be translationally 134 
repressed by 4EHP.  135 
mRNAs with long 3′ UTR generally contain more miRNA-binding sites (Cheng, 136 
Bhardwaj, & Gerstein, 2009). We examined the number of miRNA-binding sites in the 3′ 137 
UTR of the upregulated  mRNAs (Agarwal, Bell, Nam, & Bartel, 2015). mRNAs which 138 
exhibit increased translation in 4EHP-KO cells, contained significantly more predicted 139 
miRNA-binding sites (642.8, 518.4, and 442.6 for the up-regulated, unchanged and 140 
down-regulated mRNAs, respectively; p-values: 0.0004, Fig. 1C). We also calculated the 141 
density of miRNA-binding sites per 100-nucleotide of 3´ UTR and found 22.9, 22.1, and 142 
21.1 for the up-regulated, unchanged and down-regulated mRNAs, respectively (p-143 
values: 0.0063, Fig. 1D), indicating a greater density of miRNA-binding sites in 3´ UTR 144 
of upregulated  mRNAs. These findings are in agreement with our previous report 145 
showing that 4EHP contributes to the translational silencing of miRNA targets by 146 
displacing eIF4E from the mRNA cap (Chapat et al., 2017). To verify that this 147 
mechanism affects the upregulated  mRNAs, we performed RNA immunoprecipitation 148 
(RIP) with an anti-eIF4E antibody in WT and 4EHP-KO MEFs. IP resulted in specific 149 
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recovery of eIF4E (Fig. S1D). We examined the enrichment of the top 3 most 150 
translationally upregulated mRNAs in 4EHP-KO cells (Tmed7, Slc35e1 and Klhl21; 151 
Supplementary file 1) among the eIF4E-bound mRNAs (Fig. 1E). Slc35e1 and Klhl21 152 
but not Tmed7 mRNAs were significantly enriched in eIF4E IP in 4EHP-KO cells in 153 
comparison with WT (Fig. 1E). Lyar and Iqgap1, which were among the most significant 154 
translationally down-regulated mRNAs, were not enriched in eIF4E IP as a consequence 155 
of 4EHP loss (Fig. 1F). These data show increased binding of eIF4E to the upregulated   156 
mRNAs in 4EHP-KO cells, and indicate that 4EHP blocks the physical association of its 157 
target mRNAs with eIF4E. 158 
4EHP-depletion impinges on cell viability and ERK1/2 phosphorylation. 159 
It was reported that while 4EHP expression is dispensable for growth in cell culture under 160 
physiological conditions, it is required under low oxygen conditions (Uniacke, Perera, 161 
Lachance, Francisco, & Lee, 2014). However, at variance with these findings, we found 162 
that 4EHP-KO MEFs grew significantly slower than their WT counterparts (48±3 % less 163 
on day 6; p=0.002) under standard cell culture conditions (5% CO2 and 20% O2) (Fig. 164 
2A, S2A and S2B). Cell cycle analysis by FACS showed that the slow proliferation of 165 
4EHP-KO cell populations is likely due to a decrease of the percentage of cells in S phase 166 
(30.3% and 21.4% for WT and KO cells, respectively; p=0.003), concomitant with an 167 
increase in the G0/G1 phase, compared with WT cells (50.2% and 57.7% for WT and KO 168 
cells, respectively; p=0.004, Fig. S2C). Consistently, depletion of 4EHP by shRNAs 169 
caused a dramatic reduction in proliferation of U251 (<90% at day 4; Fig. 2B, S2D), and 170 
U-87 human glioblastoma cell lines (Fig. S2E and S2F). Notably, FACS analysis showed 171 
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that unlike in MEFs, depletion of 4EHP in U251 cells increased the fraction of cells in 172 
sub-G1, which is associated with apoptosis (shCTR: 0.9%, sh4EHP#1: 15.5%, and 173 
sh4EHP#2: 11.4; Fig. 2C and S2G). Accordingly, 4EHP depletion in U251 cells also 174 
induced the accumulation of cleaved-PARP (C-PARP), a marker of apoptosis (Fig. S2D).  175 
The signaling pathways RAS/RAF/MEK/ERK and PI3K/mTOR control cell 176 
proliferation, growth and apoptosis, either in parallel or by converging on common 177 
downstream factors (Cagnol & Chambard, 2010; Laplante & Sabatini, 2012; Mendoza et 178 
al., 2011). We determined the phosphorylation levels of ERK1/2 and ribosomal protein 179 
S6 (RPS6) as respective markers of RAS/RAF/MEK/ERK and PI3K/mTOR activity by 180 
western blot (WB) analysis. While RPS6 phosphorylation remained unchanged, ERK1/2 181 
phosphorylation (Thr202/Tyr204; pERK) was more than 80% reduced in 4EHP-KO 182 
MEFs in comparison with WT (Fig 2D). A similar result was obtained in U251 cells upon 183 
4EHP-knockdown (Fig. S2H). However, phosphorylation of MEK, the immediate 184 
upstream kinase of ERK1/2, remained unchanged in 4EHP-depleted cells (Fig. 2D and 185 
S2H). These results suggest that the expression or activity of a factor upstream of 186 
ERK1/2, which is independent of MEK, is deregulated in 4EHP-depleted cells. 187 
4EHP represses Dusp6 mRNA translation.  188 
We interrogated the 4EHP-KO MEF ribosome profiling data to identify candidate genes 189 
that could explain the strong impact of 4EHP on ERK1/2 phosphorylation. Interestingly, 190 
the mRNA encoding DUSP6, a potent and specific ERK1/2 phosphatase (Caunt & Keyse, 191 
2013), was among the most translationally up-regulated transcripts in 4EHP-KO MEFs as 192 
compared to WT MEFs, with no significant change in its mRNA levels (Supplementary 193 
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file 1). As expected, depletion of DUSP6 by shRNAs in U251 cells elicited ERK1/2 194 
phosphorylation (Fig. S2I). To determine whether increased translation of Dusp6 mRNA 195 
in 4EHP-KO MEFs is because of enhanced initiation, which is the rate limiting step in 196 
translation, we performed polysome profiling, which resolves mRNAs on a sucrose 197 
gradient according to the number of ribosomes with which they associate (Fig. S2J). 198 
While the distribution of the Gapdh mRNA along the sucrose gradient was similar in 199 
4EHP-KO and WT cells, the Dusp6 mRNA was shifted towards heavier fractions in the 200 
4EHP-KO cells (Fig. 2E), demonstrating augmented initiation. Consistent with greater 201 
translation efficiency, DUSP6 protein amount was markedly increased in 4EHP-KO MEF 202 
as compared to WT (Fig. 2F). Up-regulation of DUSP6 protein level was also observed in 203 
U251 cells upon 4EHP knockdown in comparison with shCTR-treated cells (Fig. S2K). 204 
In contrast, expression of DUSP7, another member of the DUSP phosphatase family, was 205 
not affected by 4EHP depletion (Fig. S2L), attesting to the specificity of 4EHP loss for 206 
mRNA translation. 4EHP depletion did not affect the abundance (Fig. S2M) or stability 207 
of Dusp6 mRNA (Fig. S2N). Importantly, restoring 4EHP expression in 4EHP-KO MEFs 208 
significantly reduced DUSP6 protein levels (~3-fold repression; Fig. 2G). Taken 209 
together, these data demonstrate that 4EHP controls expression of the ERK1/2 210 
phosphatase DUSP6 at the level of mRNA translation initiation. 211 
Dusp6 3´ UTR confers translational sensitivity to 4EHP. 212 
To determine whether 4EHP regulates Dusp6 translation by displacing eIF4E from the 213 
cap (Chapat et al., 2017; Cho et al., 2005), we examined the association of Dusp6 mRNA 214 
with eIF4E in WT versus 4EHP-KO MEFs, using RIP. While Dusp6 mRNA levels were 215 
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not significantly different between the WT and 4EHP-KO cells (Fig. 3A; for 216 
corresponding WB analysis, see Fig. S1D), an 8-fold enrichment of Dusp6 mRNA was 217 
detected in eIF4E IP from 4EHP-KO MEF lysates, as compared to WT (Fig. 3A). As 218 
control, Dusp7 mRNA was not enriched in eIF4E IP from 4EHP-KO MEFs lysates. 219 
These data lend further support to our model of displacement of eIF4E from the cap by 220 
4EHP, and demonstrate that this mechanism causes translational repression of Dusp6 221 
mRNA. 222 
3´ UTRs effect mRNA translation through trans-acting factors such as RNA-binding 223 
proteins (RBPs) and miRNAs (Szostak & Gebauer, 2013). DUSP6 expression is 224 
regulated by miRNAs including miR-145 (Y. F. Gu et al., 2015), miR-181a (Li et al., 225 
2012), and the RBP PUM2 (Bermudez et al., 2011a), a homolog of Drosophila pumilio. 226 
We thus sought to study the role of the 3´ UTR of Dusp6 mRNA in translational 227 
repression by 4EHP. To this end, 3´ rapid amplification of cDNA ends (3´ RACE) 228 
analysis was performed to amplify the 3´ UTR of Dusp6 mRNA in U251 cells. A 1192-229 
nucleotides segment was amplified (Supplementary file 2) and cloned into the 230 
psiCHECK-2 luciferase reporter vector. The resulting construct was transfected into 231 
HEK293T cells along with control siRNA (siCTR) or siRNA against 4EHP (si4EHP), or 232 
its partners CNOT1 (siCNOT1) and 4E-T (si4E-T). In the siCTR-transfected cells, the 3´ 233 
UTR of Dusp6 mRNA caused a 3-fold repression in comparison with the backbone 234 
reporter alone (Fig. 3B). However, knockdown of 4EHP or its partners CNOT1 and 4E-T 235 
significantly de-repressed the psiCHECK-Dusp6-3´UTR reporter (38%, 49%, and 44% 236 
respectively as compared to siCTR; Fig. 3B), thus supporting the role of CCR4-NOT/4E-237 
T/4EHP pathway in Dusp6 mRNA translational repression. Consistent with the latter 238 
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results, knockdown of CNOT1 and CNOT9, two critical subunits of the CCR4-NOT 239 
complex, also led to an increase of DUSP6 protein amounts in U251 cells (1.4 and 2.2-240 
folds, respectively; Fig. S3A).  241 
We next mapped the repressive activity of 4EHP to elements of the 3´ UTR of Dusp6 242 
mRNA. To this end, we sub-cloned six ∼200 nt fragments of the 3´ UTR into the 243 
psiCHECK-2 luciferase reporter (Fig. S3B). A segment harbouring both miR-145 and 244 
miR-181a binding sites exerted the strongest repression on the reporter (1.5 fold; p=0001, 245 
Fig. 3C), which was alleviated upon 4EHP knockdown (Fig. 3C). To identify which 246 
miRNA is responsible for repression of Dusp6 mRNA, we used specific inhibitors to 247 
block miR-145, miR-181a, and miR-124 in U251 cells. While blocking miR-124 and 248 
miR-181a did not affect DUSP6 expression, a miR-145 inhibitor increased DUSP6 249 
accumulation to a similar degree as knockdown of 4EHP (Fig. 3D), without affecting the 250 
stability of the Dusp6 mRNA (Fig. S3C). We further investigated the effect of miR-145 251 
inhibitor on a luciferase reporter with the full-length Dusp6 3´ UTR. Unlike the control 252 
reporter, the expression of the reporter containing Dusp6 3´ UTR was significantly de-253 
repressed in the presence of miR-145 inhibitor (1.25 fold repression compared with 2.09 254 
for mock inhibitor; Fig. 3E). Consistent with our observation that siRNA depletion of 255 
4EHP in HEK293T cells de-repressed the Dusp6 3´ UTR reporter (Fig. 3B), silencing of 256 
the same reporter was fully reversed in a 4EHP-KO HEK293 cells (Fig. 3E). No de-257 
repression by the miR-145 inhibitor was observed in 4EHP-KO HEK293 cells (Fig. 3E). 258 
This confirms the requirement for 4EHP in miR-145-induced translational silencing of 259 
Dusp6 mRNA. Taken together, these data demonstrate that the Dusp6 mRNA translation 260 
is controlled by its 3´ UTR through the miRNA/CCR4-NOT/4E-T/4EHP pathway.  261 
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De-repression of DUSP6 impedes ERK activity and proliferation in 4EHP-depleted 262 
cells. 263 
We next sought to determine the consequences of DUSP6 de-repression on ERK 264 
signaling and functions in 4EHP-KO MEFs. We used a selective small molecule inhibitor 265 
of DUSP6, 2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride (BCI) (Molina 266 
et al., 2009; Shojaee et al., 2015). Treatment of 4EHP-KO cells with BCI increased 267 
pERK1/2 to levels comparable with untreated WT cells within 30 minutes (Fig. 4A). 268 
Similar results were obtained with U251 cells expressing an shRNA against 4EHP (Fig. 269 
S4A). These data confirm that reduced ERK1/2 phosphorylation in 4EHP-depleted cells 270 
is due to increased DUSP6 activity. Next, we examined the consequence of DUSP6 271 
inhibition on proliferation of 4EHP-depleted cells by using shRNAs to knockdown 272 
DUSP6 in WT and 4EHP-KO cells (Fig. S4B). While DUSP6 knockdown did not have a 273 
detectable impact on WT cells proliferation, depletion of DUSP6 in 4EHP-KO cells 274 
markedly augmented their proliferation (42% increase for sh4EHP#1 [p=0.007] and 65% 275 
increase for sh4EHP#2 [p=0.004] on day 4; Fig. 4B). This result demonstrates that the 276 
reduced proliferation of 4EHP-KO cells is at least partially due to de-repression of 277 
DUSP6. 278 
Extracellular signals or mutations in Ras or Raf, which occur frequently in cancers, 279 
activate a phosphorylation cascade that results in phosphorylation and activation of ERK 280 
signaling (Samatar & Poulikakos, 2014). We examined whether 4EHP-depletion and the 281 
resulting increased DUSP6 expression could interfere with ERK1/2 phosphorylation in 282 
response to upstream activation of RAS. To this end, we expressed a constitutively active 283 
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mutant KRAS (G12V) (Prior, Lewis, & Mattos, 2012) and monitored ERK signaling by 284 
WB and proliferation assays. While ERK1/2 phosphorylation was increased by forced 285 
KRAS activity in WT MEFs, pERK levels remained unchanged in 4EHP-KO MEFs (Fig. 286 
4C). Consistent with these results, WT MEFs proliferation was slightly increased upon 287 
enforced KRAS activity, but remained unaffected in 4EHP-KO MEFs (Fig. S4C).  288 
Taken together, the data demonstrate that 4EHP up-regulates ERK1/2 phosphorylation by 289 
effecting the miRNA-induced translational repression of Dusp6 mRNA, and that 290 
depletion of 4EHP limits ERK activation by upstream signaling (Fig. 4D, model). 291 
DISCUSSION 292 
We previously demonstrated that the cap-binding protein 4EHP acts as an effector of 293 
translational repression instigated by miRNAs. Here, we identify Dusp6 mRNA as a 294 
functionally critical target of this silencing mechanism, which occurs in the absence of 295 
mRNA decay. Translational repression of Dusp6 mRNA by the combined action of 296 
4EHP and miR-145 down-regulates the MAPK/ERK signaling cascade and its output in 297 
cell proliferation and survival. The 4EHP/miRNA repression mechanism thus engenders 298 
important biological consequences in homeostasis and disease. 299 
The relative contributions of translational repression and mRNA decay in miRNA-300 
mediated silencing are in dispute. Several large-scale studies reported that mammalian 301 
miRNAs predominantly act by decreasing target mRNA levels (Baek et al., 2008; 302 
Eichhorn et al., 2014; Guo, Ingolia, Weissman, & Bartel, 2010), while others showed that 303 
miRNAs affect the expression of target genes by translation inhibition (Jin et al., 2017; 304 
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Selbach et al., 2008; Yang, Chaerkady, Beer, Mendell, & Pandey, 2009). It was 305 
convincingly demonstrated in in vitro and in vivo studies that translational repression 306 
precedes target mRNA decay (Bazzini, Lee, & Giraldez, 2012; Bethune, Artus-Revel, & 307 
Filipowicz, 2012; Djuranovic, Nahvi, & Green, 2012; Fabian et al., 2009; Mathonnet et 308 
al., 2007). Because of their intricate nature, the exact contribution of either aspect of 309 
miRNA-mediated silencing in biological decisions has remained elusive. Our data 310 
demonstrate that 4EHP effects miRNA-mediated translational repression of Dusp6 311 
mRNA, but not mRNA stability. The relative contribution of translational repression and 312 
mRNA degradation to miRNA-mediated silencing may thus depend on the target mRNAs 313 
and on the cellular context. Expression of miRISC core and accessory components, post-314 
translational modifications, translation efficiency, RNA structure within a 3´ UTR, or 315 
interactions with RNA-binding proteins (RBPs) may interfere or promote miRISC 316 
activities (Cottrell, Chaudhari, Cohen, & Djuranovic, 2018; Cottrell, Szczesny, & 317 
Djuranovic, 2017; Kedde et al., 2010; Kundu, Fabian, Sonenberg, Bhattacharyya, & 318 
Filipowicz, 2012; Long et al., 2007). The RBPs PUM2 and TTP were implicated in the 319 
post-transcriptional repression of Dusp6 mRNA, presumably in a CCR4-NOT-dependent 320 
mechanism (Bermudez et al., 2011b; Galgano et al., 2008). Since the abundance of RBPs 321 
varies in tissues and under pathological conditions, it is conceivable that the potency and 322 
the nature of the miRNA-mediated silencing mechanism are modulated by such RBPs.  323 
Our study underscores the importance of translational control in regulation of the ERK 324 
signaling pathway. Indirect up-regulation of ERK1/2 phosphorylation by 4EHP, via 325 
repression of Dusp6 translation, explains the diminished cell proliferation in 4EHP-KO 326 
MEF cells and apoptosis observed in 4EHP-depleted U251 and U87 cells. A notable 327 
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observation in our study is the impairment of the RAS/RAF/MEK/ERK pathway in 328 
4EHP-depleted cells. Specifically, constitutively active RAS fails to increase ERK1/2 329 
phosphorylation in 4EHP-KO MEFs. This can be explained by increased DUSP6 330 
expression in 4EHP-KO cells, which effectively impairs phosphorylation of ERK1/2 331 
downstream of RAS. Interestingly, over-expression of constitutively active RAS (Park, 332 
Lee, Shin, & Kim, 2014), or BRAF (Agrawal et al., 2014), also induces DUSP6 333 
expression constituting a negative feedback loop. The feedback loop restrains the activity 334 
of the RAS/RAF/MEK/ERK pathway upon induction by stimuli (e.g. growth factors). 335 
Thus, increasing DUSP6 expression by inhibiting 4EHP can potentially repress ERK 336 
pathway activation. While several pharmacological approaches have been described for 337 
targeting eIF4E (Fischer, 2009; Graff et al., 2007), to date no specific inhibitor of 4EHP 338 
has been discovered. The elucidation of the crystal structures of 4EHP in association with 339 
its binding partners (Peter et al., 2017; Rosettani, Knapp, Vismara, Rusconi, & Cameron, 340 
2007) may prove useful for this purpose.  341 
Our ribosome profiling data strongly suggest that translational repression through 342 
miRNA/4EHP impacts on many other mRNAs. An interesting miRNA to revisit in light 343 
of this mechanism is let-7, which suppresses tumorigenesis by directly silencing RAS 344 
expression (Johnson et al., 2005). We had previously shown that 4EHP contributes to the 345 
translational repression activity of a reporter mRNA by let-7 miRNA (Chapat et al., 346 
2017), but let-7 miRNA can also clearly instigate mRNA deadenylation and decay. The 347 
relative contributions of translation repression and mRNA decay in the function of 348 
miRNA/mRNA pairs may be further revealed by systematically addressing their epistasis 349 
with 4EHP in the relevant cellular context.  350 
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 351 
MATERIALS and METHODS 352 
List of Antibodies, siRNAs and shRNAs  353 
The following antibodies were used: rabbit anti-eIF4E2 (4EHP) (Genetex, GTX103977), 354 
mouse anti-eIF4E (BD Biosciences, 610270), rabbit anti-eIF4ENIF1 (4E-T; abcam, 355 
ab55881), rabbit anti-DDX6 (Bethyl Laboratories, A300-460A), rabbit anti-CNOT1 356 
(Proteintech, 14276-1-AP), mouse anti-α-Tubulin (Santa Cruz, sc-23948), mouse anti-β-357 
actin (Sigma, A5441), mouse anti-Flag (Sigma, F3165), rabbit anti-HA (Sigma, H6908), 358 
mouse anti-V5 tag (Invitrogen, R960-25), rabbit anti-PARP (Cell Signaling Cat# 9532S), 359 
rabbit anti-DUSP6 (abcam Cat# ab76310), rabbit anti-DUSP7 (abcam Cat# ab100921), ), 360 
rabbit anti-CNOT9 (RQCD1) (Proteintech Cat# 22503-1-AP), rabbit anti-CNOT2 (Cell 361 
Signaling Cat# 6955S), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204; Cell Signaling 362 
Cat#4370), mouse anti-MEK1/2 (Cell Signaling Cat# 4694S), rabbit anti-phospho-363 
MEK1/2 (Ser217/221; Cell Signaling Cat# 9121S), rabbit anti-phospho-RPS6 364 
(Ser240/244) (Cell Signaling Cat# 2215), and mouse anti-RPS6 (C-8). 365 
The following siRNA and shRNAs were used: ON-TARGETplus Non-targeting Control 366 
Pool (Dharmacon, D-001810-10-05), 4EHP siRNA SMARTpool (Dharmacon, L-367 
019870-01), eIF4ENIF1 (4E-T) siRNA SMARTpool (Dharmacon, L-013237-01), Non-368 
Targeting shRNA Controls (Sigma, SHC002), and EIF4E2 shRNA (Sigma, 369 
TRCN0000152006). 370 
Cell lines and culture conditions 371 
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MEFs, U251 (ATCC), U87 (ATCC), and HEK293T (Thermo Fisher Scientific) cells 372 
were maintained in DMEM supplemented with 10% foetal bovine serum and 373 
penicillin/streptomycin in a humidified atmosphere of 5% CO2 at 37°C. Control and 374 
4EHP-knockout Flp-In T-REx 293 cells (HEK293, Thermo Fisher Scientific) were grown 375 
in high glucose DMEM (Thermo Fisher Scientific, 11965118) supplemented with 10% 376 
v/v FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 100 µg/ml 377 
zeocin and 15 µg/ml blasticidin. U251, U87, and HEK293T were tested for presence of 378 
mycoplasma contamination by LookOut® Mycoplasma PCR Detection Kit (SIGMA, 379 
MP0035). Presence of mycoplasma in HEK293 cells was tested and dismissed by 380 
mRNA-Seq as previously described (Garzia et al., 2017). 381 
Inhibition of miRNA activity 382 
The following miRNA inhibitors (Thermo Fisher Scientific, 4464084) were used: anti-383 
miR-124 (MH10421), anti-miR-145 (MH11480), anti-miR-181 (MH10691) and mirVana 384 
negative control (4464076). 200,000 U251 cells were plated in a 6-well plate and 385 
transfected with a final concentration of 50 nM of each miRNA inhibitor for 72 h using 386 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.  387 
Lentivirus production 388 
8x106 293FT (Thermo Fisher Scientific, R70007) cells were cultured in a 10-cm dish for 389 
24 h in high glucose DMEM supplemented with 10% v/v FBS. Medium was replaced by 390 
OptiMEM (Thermo Fisher Scientific, 51985091) 30 min before transfection. Lentivirus 391 
particles were produced by transfecting the HEK293FT cells using Lipofectamine 2000 392 
and 10 µg shRNA plasmid, 6.5 µg psPAX2 (Addgene, plasmid 12260) and 3.5 µg 393 
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pMD2.G (Addgene, plasmid 12259) packaging plasmids. 5 h post-transfection, the 394 
medium was replaced with fresh high glucose DMEM supplemented with 10% v/v FBS. 395 
Supernatant was collected at 48 h post-transfection, replaced with fresh medium and 396 
collected after 24 h. Viral particles were cleared by filtration (45 µm; Fisher Scientific, 397 
09-720-005) and virus titer was measured by colony formation assay using 293FT cells. 398 
The multiplicity of infection (MOI) was adjusted to ~5. Virus solution was stored at -399 
80ºC without cryopreservative in 1 ml aliquots or used to infect the cells directly in the 400 
presence of 6 µg/ml polybrene (Sigma, H9268). 401 
CRISPR-Cas9 genome engineering for generating 4EHP knockout HEK293 cell line  402 
CRISPR-Cas9-mediated genome editing of Flp-In T-REx HEK293 cells was performed 403 
as previously  described (Ran et al., 2013). Two small guide RNAs (sgRNAs) cognate 404 
to the coding region of 4EHP gene: 5´-CAACAAGTTCGACGCGTGAG and 5´-405 
TGAGCTCGTGGGACGGCCGG were designed. The top and bottom strands of each 406 
designed sgRNA were  annealed creating overhangs for cloning of the guide sequence 407 
oligos into pSpCas9(BB)-2A-GFP (Addgene, PX458, Plasmid #48138) by BbsI 408 
digestion. To generate gene knockout Flp-In T-REx HEK293 cells, we transfected 409 
130.000 cells with the corresponding guide sequence containing pSpCas9(BB)-2A-GFP 410 
plasmid. 24 hours after transfection, GFP-positive single cells were sorted by FACS 411 
into 96-well plates and cultivated until colonies were obtained. Clonal cell lines were 412 
analyzed by WB for protein depletion as well as by PCR-genotyping. The following 413 
primers were used for the PCR-genotyping: sense primer1, 5´- 414 
GCCGCCCTGAGCTGGCGTCCC; anti-sense primer1, 5´- 415 
CGGCACAGCCACCCCTCCCCC; sense primer2, 5´- 416 
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GCAGAATCTTTGGCACATTGCAGATAGTTGAGG; anti-sense primer2, 5´- 417 
GCCCTTCTGATCAACTCTACAATTCTCATATTTGTTGATACC. PCR products 418 
were cloned using the Zero Blunt PCR Cloning Kit (Thermo Fisher Scientific, K270040) 419 
and 10 clones sequenced per cell line. 420 
Real-Time RT-qPCR 421 
1 µg of DNase I-treated total RNA, purified using the TRI-Reagent, was reverse-422 
transcribed using 100 ng of random primers following the Superscript III (Invitrogen) 423 
protocol. Real time PCR was performed with SYBR Green master mix (iQ; Biorad) in a 424 
real-time PCR detection system (Mastercycler Realplex, Eppendorf). Mean values of 425 
triplicate measurements were calculated according to the –ΔΔCt quantification method, 426 
and were normalized against the expression of the indicated mRNA. Specificity was 427 
confirmed by analyzing the melting curves of PCR products. RT-qPCR results were 428 
repeated at least three times in independent experiments and representative data sets are 429 
shown. Sequences of the used primers are listed in the Supplementary file 3.  430 
3´ rapid amplification of cDNA ends (3´ RACE) analysis 431 
3′ RACE was performed with the SMARTer RACE 5′/3′ kit (Clontech, Cat # 634858). 1 432 
µg of total RNAs extracted from U251 cells was treated with DNase I (Fermentas) and 433 
cDNA was generated by the SMARTScribe Reverse Transcriptase (Clontech), according 434 
to the manufacturer's instructions. The resultant cDNA was used for PCR amplification 435 
using the human DUSP6 gene-specific forward primers (GSPs) (Supplementary file 2) 436 
together with a common Universal Reverse Primer (UPM), provided by the 437 
manufacturer. PCR products were resolved by agarose gel electrophoresis and all visible 438 
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bands were excised and digested by restriction enzymes followed by cloning into the 439 
PUC19 vector provided by the manufacturer and sequenced by Sanger sequencing. 440 
RNA immunoprecipitation (RIP) 441 
RIP was performed as described previously (Thoreen et al., 2012) with minor 442 
modifications. WT and 4EHP-KO MEFs were seeded in 3x15 cm plates (at 10x106 cells 443 
per plate) and incubated overnight. Cells were lysed in lysis buffer A (50 mM HEPES-444 
KOH (pH: 7.4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM beta-glycerophosphate, 40 445 
mM NaCl, 1% Trition X-100 and one tablet of EDTA-free protease inhibitors (Roche)) 446 
containing 40 U/ml SuperaseIn. Insoluble material was removed by centrifugation at 447 
20,000xg for 5 min at 4oC. Protein concentration was measured by Bradford assay and 2 448 
mg of lysate was pre-cleared by incubating with 50 µl of 50% protein G agarose fast flow 449 
beads (EMD Millipore, 16-266) for 2 h at 4ºC with gentle agitation. The cleared lysates 450 
were collected by centrifugation at 3,000xg for 1 min at 4ºC and collecting the 451 
supernatant. In parallel 2 µg of anti-eIF4E antibody was incubated with 50 µl of 50% 452 
protein G agarose fast flow beads for on an end-over-end rotator for 2 h at 4ºC. For IP, 453 
the pre-cleared lysates were incubated with the antibody + bead mixture, in 1 ml total 454 
volume on an end-over-end rotator for 2 h at 4ºC. The precipitated beads were then 455 
washed 3x with 1 ml buffer A, twice with buffer B (15 mM HEPES-KOH (pH 7.4), 7.5 456 
mM MgCl2, 100 mM KCl, 2 mM DTT and 1.0% Triton X-100), and resuspended in 100 457 
µl buffer B. 10 µl of the final mix was used for WB and the remaining was used for RNA 458 
extraction.  459 
Cycloheximide treatment and hypotonic cell lysis 460 
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Cells were pretreated with cycloheximide (Bioshop Canada Cat#CYC003) (100 µg/ml) 461 
for 5 min, and lysed in hypotonic buffer (5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 462 
mM KCl, 1x protease inhibitor cocktail (EDTA-free), 100 µg/ml cycloheximide, 2 mM 463 
DTT, 200 U/ml RNaseIn, 0.5% (v/w) Triton X-100, and 0.5% (v/w) Sodium 464 
Deoxycholate), to isolate the polysomes. 465 
Collection of ribosome footprints (RFPs) 466 
Ribosome profiling was performed as described (Ingolia, Brar, Rouskin, McGeachy, & 467 
Weissman, 2012), with minor modifications. Briefly, 500 µg of the ribonucleoproteins 468 
were subjected to ribosome footprinting by RNase I treatment at 4oC for 45 min with 469 
end-over-end rotation. Monosomes were pelleted by ultracentrifugation in a 34% sucrose 470 
cushion at 70,000xrpm for 3h and RNA fragments were extracted twice with acid phenol, 471 
once with chloroform, and precipitated with isopropanol in the presence of NaOAc and 472 
GlycoBlue. Purified RNA was resolved on a denaturing 15% polyacrylamide-urea gel 473 
and the section corresponding to 28-32 nucleotides containing the RFPs was excised, 474 
eluted, and precipitated by isopropanol. 475 
Random RNA fragmentation and mRNA-Seq 476 
100 µg of cytoplasmic RNA was used for mRNA-Seq analysis. Poly (A)+ mRNAs were 477 
purified using magnetic oligo-dT DynaBeads (Invitrogen) according to the 478 
manufacturer’s instructions. Purified RNA was eluted from the beads and mixed with an 479 
equal volume of 2X alkaline fragmentation solution (2 mM EDTA, 10 mM Na2CO3, 90 480 
mM NaHCO3, pH 9.2) and incubated for 20 min at 95oC. Fragmentation reactions were 481 
mixed with stop/precipitation solution (300 mM NaOAc pH 5.5 and GlycoBlue), 482 
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followed by isopropanol precipitation. Fragmented mRNA was size-selected on a 483 
denaturing 10% polyacrylamide-urea gel and the area corresponding to 35-50 nucleotides 484 
was excised, eluted, and precipitated with isopropanol. 485 
Library preparation and sequencing 486 
Fragmented mRNAs and RFPs were dephosphorylated using T4 polynucleotide kinase 487 
(New England Biolabs). Denatured fragments were resuspended in 10 mM Tris (pH 7) 488 
and quantified using the Bio-Analyzer Small RNA assay (Agilent). 10 pmol of RNA was 489 
ligated to the 3′-adaptor with T4 RNA ligase 1 (New England Biolabs) for 2 h at 37°C. 490 
Reverse transcription was carried out using oNTI223 adapter (Illumina) and SuperScript 491 
III reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. 492 
Products were separated from the empty adaptor on a 10% polyacrylamide 493 
Tris/Borate/EDTA-urea (TBE-urea) gel and circularized by CircLigase (Epicentre). 494 
Ribosomal RNA amounts were reduced by subtractive hybridization using biotinylated 495 
rDNA complementary oligos (Ingolia et al., 2012). The mRNA and ribosome-footprint 496 
libraries were amplified by PCR (12 cycles) using indexed primers and quantified using 497 
the Agilent BioAnalyzer High-Sensitivity assay. DNA was then sequenced on the HiSeq 498 
2000 platform with read length of 50 nucleotides (SR50) according to the manufacturer’s 499 
instructions, with sequencing primer oNTI202 500 
(5CGACAGGTTCAGAGTTCTACAGTCCGACGATC). 501 
Analysis of Ribosome profiling data 502 
Prior to alignment, linker and polyA sequences were removed from the 3´ ends of reads. 503 
Bowtie v0.12.7 (allowing up to 2 mismatches) was used to perform the alignments. First, 504 
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reads that aligned to rRNA sequences were discarded. All remaining reads were aligned 505 
to the mouse genome (mm10). Finally, still-unaligned reads were aligned to the mouse 506 
known canonical transcriptome that includes splice junctions. Reads with unique 507 
alignments were used to compute the total number of reads at each position. Footprints 508 
and mRNA densities were calculated in units of reads per kilobase per million (RPKM) 509 
to normalize for gene length and total reads per sequencing run. The expression patterns 510 
were examined for genes that had more than 150 uniquely aligned reads of mRNA and 511 
footprints in one of the samples. The Babel computational framework was used to 512 
quantitatively evaluate if there are genes that are differently translated in KO cells (1). 513 
The 5´ and 3´ UTRs were obtained from the UCSC Genome Browser. For translationally 514 
induced or repressed genes the length of 5´ and 3´ UTRs were calculated and compared 515 
using Welch Two Sample t-test. Predicted miRNA sites were retrieved from 516 
TargetScanMouse. Both conserved and non-conserved sites were taken into account. The 517 
number of miRNA sites per 100 bp of 3´ UTR was calculated using the 3´ UTR lengths 518 
published on TargetScanMouse. The GEO accession numbers for the sequencing data 519 
reported in this paper is GSE107826.  520 
RNA stability assay 521 
300,000 cells were plated in 6-well plates and 5 μg/ml actinomycin D (Sigma) was added 522 
to the culture medium at the indicated times. RNA was isolated by using Tri Reagent 523 
(Sigma-Aldrich), according to the manufacturer’s protocol and the stability of the 524 
indicated transcript was measured by RT-qPCR with the primers indicated in 525 
Supplementary file 3.  526 
Preparation of reporter constructs 527 
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To generate luciferase reporter plasmids, a modified version of psiCHECK-2 (Promega) 528 
containing the Gateway cassette C.1 (Invitrogen) at the 3´ end of the firefly luciferase (F-529 
Luc) gene was used as described before (Suffert et al., 2011). The 3′ UTR sequence of 530 
Dusp6 mRNA inserted in the PUC19 vector was obtained from the U251 cells by 3´ 531 
RACE assay. The attB-Dusp6 fragment was obtained by PCR with the primers indicated 532 
in Supplementary file 3, cloned into pDONR/Zeo (Invitrogen) and recombined in the 533 
modified psiCHECK-2 vector by Gateway cloning. The fragments of the 3′ UTR of 534 
Dusp6 were obtained by PCR from the psiCHECK-Dusp6 3’UTR vector and inserted as 535 
XhoI-NotI fragments into the psiCHECK-2 vector at the 3′-end of the Renilla luciferase 536 
gene (R-Luc). Sequences of the used primers are listed in the Supplementary file 3. 537 
Luciferase reporter assay 538 
HEK293T and U251 cells (15000 cell/well) were co-transfected in a 24-well plate with 539 
10 ng psiCHECK-Dusp6 3´ UTR. For 4EHP knockdown, 4x106 cells were plated in a 10 540 
cm culture dish and transfected with a final concentration of 25 nM of siRNA duplexes 541 
using Lipofectamine 2000 according to the manufacturer’s instructions. After 24 h, cells 542 
were plated in a 24-well plate and transfected a second time with the psiCHECK vectors 543 
as described above. Cells were lysed 24 h after transfection. Luciferase activities were 544 
measured with the Dual-Luciferase Reporter Assay System (Promega) in a GloMax 545 
20/20 luminometer (Promega). For experiments with miRNA inhibitors, HEK293 cells 546 
were co-transfected in a 24-well plate with 10 ng psiCHECK-Dusp6 3´ UTR and miRNA 547 
inhibitors were added to the transfection mixture at a final concentration of 50 nM. 548 
 549 
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 820 
Figure legends 821 
Figure 1 with 1 supplement: 4EHP controls translation of a subset of mRNAs. (A) 822 
The log2 ratio plot of abundance of ribosome footprints (RFP) and mRNAs in 4EHP-KO 823 
vs WT MEFs is shown. R2 indicates Pearson correlation. (B) Comparison of 3´ UTR 824 
length of mRNAs up- or downregulated in 4EHP-KO MEFs. p-values: Up vs. Down: 825 
2.26e-22, Up vs. Unchanged: 4.26e-17. (C) miRNA-binding sites in the 3´ UTR of 826 
mRNAs identified in (A). p-values: Up vs. Down: 0.000019, Up vs. Unchanged: 0.00040. 827 
(D) miRNA-binding site density (number of miRNA-binding sites per 100-nucleotide of 828 
3’ UTR) in mRNA identified in (A). p-values: Up vs. Down: 0.000043, Up vs. 829 
Unchanged: 0.0063. (E) RNA-immunoprecipitation (RIP) analysis of the association of 830 
eIF4E with 4EHP targets in 4EHP-KO MEFs. eIF4E was immunoprecipitated using a 831 
monoclonal antibody against eIF4E from WT and 4EHP-KO MEFs. Levels of the 832 
indicated mRNAs (normalized to β-actin mRNA) in the inputs and eIF4E-bound mRNAs 833 
were analyzed by RT–qPCR. Data are mean ± SD (n = 3). The p-value was determined 834 
by two-tailed Student's t‐test: (ns) non-significant, (*) P < 0.05; (**) P < 0.01; (***) P < 835 
0.001.  836 
Figure 2 with 1 supplement: Depletion of 4EHP expression affects cell proliferation, 837 
survival, and ERK1/2 phosphorylation. (A) Cell proliferation assay. WT and 4EHP-838 
KO MEFs were seeded in 6-well plates and trypsinized after the indicated time points and 839 
cell numbers determined using a hematocytometer. Data are mean ± SD (n = 3). (B) Cell 840 
proliferation assay. U251 cells with stable expression of shCTR (control), sh4EHP#1, and 841 
sh4EHP#2 were seeded in 6-well plates. Cells were trypsinized after the indicated time 842 
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points and cell numbers determined using a hematocytometer. Data are mean ± SD (n = 843 
3). (C) Quantitation of cell death by FACS assay; Sub-G population was considered as 844 
“Dead” and G0/1, S and G2/M population was combined as “Live”. Data are mean ± SD 845 
(n = 3). (D) WB for the indicated proteins in the WT and 4EHP-KO MEFs. (E) Polysome 846 
profiling/RT-PCR; RNA was extracted from each fraction (collected as described in Fig. 847 
S2J), subjected to electrophoresis on agarose gel and visualized, using Ethidium Bromide 848 
(EtBr) staining. RT-PCR analyses of total RNA in each fraction was carried out with 849 
primers specific for Dusp6 and Gapdh mRNAs. (F) WB on the indicated proteins in WT 850 
and 4EHP-KO MEFs. (G) WB for the indicated proteins in the WT and 4EHP-KO MEFs, 851 
expressing a v5-tagged GFP (GFP-v5) or v5-tagged 4EHP (4EHP-v5).  852 
Figure 3 with 1 supplement: 4EHP enables miRNA-mediated silencing of Dusp6 853 
mRNA. (A) RIP analysis of the association of eIF4E with Dusp6 mRNA in WT and 854 
4EHP-KO MEFs.  eIF4E was immunoprecipitated using a monoclonal antibody. Levels 855 
of the indicated mRNAs (normalized to β-actin mRNA) in the inputs and eIF4E-bound 856 
mRNAs were analyzed by RT–qPCR. Data are mean ± SD (n = 3). (B) Top; Schematic 857 
representation of the psiCHECK-FL-Dusp6 3´ UTR reporter. Bottom; CTR, CNOT1, 4E-858 
T, or 4EHP-knockdown cells were co-transfected with psiCHECK-FL-Dusp6 3´ UTR 859 
reporter or the psiCHECK reporter (as control) in HEK293T cells. Luciferase activity 860 
was measured 24 h after transfection. Firefly (F-Luc) values were normalized against 861 
Renilla (R-Luc) levels, and repression fold was calculated for the psiCHECK-FL-Dusp6 862 
3´ UTR reporter relative to psiCHECK reporter level for each condition. Data are mean ± 863 
SD (n = 3). (C) The psiCHECK reporter (control) or psiCHECK-RL with truncated 864 
fragments of the Dusp6 3´ UTR were transfected into the HEK293T cells. Luciferase 865 
 34 
activity was measured 24 h after transfection. R-Luc values were normalized against F-866 
Luc levels, and repression fold was calculated for the psiCHECK-RL-Dusp6 3´ UTR 867 
reporter relative to psiCHECK reporter level for each condition. Data are mean ± SD (n = 868 
3). (D) WB for the indicated proteins in U251 cells transfected with si4EHP or the 869 
indicated miRNA inhibitors. (E) The psiCHECK reporter (control) or psiCHECK-FL-870 
Dusp6 3´ UTR were co-transfected along with the mock or miR-145 inhibitor in the 871 
control (CTR) or 4EHP-KO HEK293 cells. Luciferase activity was measured 24 h after 872 
transfection. F-Luc values were normalized against R-Luc levels, and repression fold was 873 
calculated relative to the psiCHECK reporter/control inhibitor for each condition. Data 874 
are mean ± SD (n = 3). The p-values was determined by two-tailed Student's t‐test: (ns) 875 
non-significant, (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.  876 
Figure 4 with 1 supplement: De-repression of DUSP6 in 4EHP-depleted cells 877 
impedes on ERK activity and cell proliferation. (A) Time course WB analyses of BCI-878 
treated WT and 4EHP-KO MEFs. (B) Cell proliferation assay. WT and 4EHP-KO MEFs 879 
with stable expression of shCTR, shDusp6#1, and shDusp6#2 were seeded in 6-well 880 
plates. Cells were trypsinized after the indicated time points and cell numbers determined 881 
using a hematocytometer. Data are mean ± SD (n = 3). (C) WB for the indicated proteins 882 
in the WT and 4EHP-KO MEFs, with stable expression of a constitutively active mutant 883 
of KRAS (G12V). (D) Model of regulation of MAPK/ERK pathway activity by 4EHP 884 
through translational control of the Dusp6 mRNA. Upon phosphorylation by MEK, ERK 885 
translocates to the nucleus and activates the Dusp6 gene. The Dusp6 transcript is then 886 
exported to the cytoplasm and translated. miRNAs control the translation of Dusp6 887 
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mRNA via the CCR4-NOT/4E-T/4EHP complex and thus regulate the MAPK/ERK 888 
pathway activity.  889 
Figure 1—figure supplement 1: Analysis of 4EHP-sensitive mRNAs by ribosome 890 
profiling. (A) Summary of workflow used to identify 4EHP-sensitive mRNAs 891 
by ribosome profiling. (B) Correlation between replicates in mRNA-Seq and ribosome 892 
profiling datasets. R2 indicates Pearson correlation. (C) Comparison of 5´ UTR length in 893 
mRNAs identified by Babel analysis as up- or down-regulated in 4EHP-KO MEFs. p-894 
values: Up vs. Down: 2.68e-06, Up vs. Unchanged: 0.038. (D) WB analysis of the 895 
indicated protein in the eIF4E RIP assay (related to Fig. 1E and 3A). eIF4E was 896 
immunoprecipitated using a monoclonal antibody in WT and 4EHP-KO MEFs. 897 
Precipitated proteins were separated by SDS-PAGE and probed with the specified 898 
antibodies.  899 
Figure 2—figure supplement 1: Cell proliferation and translational regulation of 900 
Dusp6 expression is affected by 4EHP depletion. (A) WB for the indicated proteins in 901 
the WT and 4EHP-KO MEFs. (B) Cell proliferation was assessed using Sulforhodamine 902 
B (SRB assay) as described in the “METHODS” section. Data are mean ± SD (n = 3). 903 
(C) Top; Representative cell cycle profiles of the WT and 4EHP-KO MEFs stained with 904 
Propidium Iodide and analyzed by FACS. Bottom; quantitation of cell cycle profiles. 905 
Data are mean ± SD (n = 3). (D) WB for the indicated proteins in control and stable 906 
4EHP-knockdown U251 cells. (E) WB for the indicated proteins in the control and stable 907 
4EHP-knockdown U87 cells. (F) Cell proliferation assay; U87 cells with stable 908 
expression of shCTR, sh4EHP#1, and sh4EHP#2 were seeded in 6-well plates. Cells 909 
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were trypsinized after the indicated time points and cell numbers determined using a 910 
hematocytometer. Data are mean ± SD (n = 3). (G) FACS assay. Representative cell 911 
cycle profiles of shCTR, sh4EHP#1, and sh4EHP#2 U251 cells stained with Propidium 912 
Iodide and analyzed by FACS. (H) WB for the indicated proteins in the control and stable 913 
4EHP-knockdown U251 cells. (I) WB for the indicated proteins in the control and stable 914 
Dusp6-knockdown U251 cells. (J) Polysome profiling; cytoplasmic extract from WT and 915 
4EHP-KO MEFs was fractioned by centrifugation on a 10–50% sucrose gradient. 916 
Fourteen fractions were collected while 254-nm absorbance was recorded. (K) WB for 917 
the indicated proteins in control (shCTR) and 4EHP-knockdown (sh4EHP) U251 cells. 918 
(L) WB for the indicated proteins in the control and stable 4EHP-knockdown U251 cells. 919 
(M) RT-qPCR analysis of Dusp6 mRNA in shCTR and sh4EHP U251 cells. Values are 920 
normalized to β-actin. Data are mean ± SD (n = 3). (N) RNA stability assay of Dusp6 921 
mRNA in shCTR and sh4EHP U251 cells. The amount of RNA at different time points 922 
was determined by reverse RT-qPCR. Values are normalized to 28S rRNA. Data are 923 
mean ± SD (n = 3).  924 
Figure 3—figure supplement 1: Repression of DUSP6 expression by CCR4-NOT 925 
complex. (A) WB for the indicated proteins in control or siRNA transfected U251 cells. 926 
(B) Diagram of Dusp6 mRNA 3´ UTR, predicted miRNA binding sites, pumilio 927 
responsive element (PRE), and truncation fragments of the UTR created for cloning into 928 
the reporter construct used in Fig. 3C. (C) RNA stability assay of Dusp6 mRNA in Mock 929 
and miR-145-inhibitor transfected cells. The quantity of RNA at different time points was 930 
determined by reverse RT-qPCR. Values are normalized to 28S rRNA. Data are mean ± 931 
SD (n = 3). (D) Sequence alignment of 10 cloned PCR products amplified from the 932 
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genomic segment of 4EHP targeted by 5´-TGAGCTCGTGGGACGGCCGG sgRNA 933 
showing the disruption of the coding sequence (related to Figure 3E).  934 
Figure 4—figure supplement 1: DUSP6-mediated repression of ERK activity and 935 
cell proliferation in 4EHP-depleted cells. (A) Time course analyses of BCI-treated 936 
control and 4EHP-knockdown U251 cells by WB for the indicated proteins. (B) WB for 937 
the indicated proteins in the control or Dusp6-knockdown WT and 4EHP-KO MEFs. (C) 938 
Cell proliferation assay. WT and 4EHP-KO MEFs, with stable expression of a 939 
constitutively active mutant KRAS (G12V) were seeded in 6-well plates. Cells were 940 
trypsinized after the indicated time points and cell numbers determined using a 941 
hematocytometer. Data are mean ± SD (n = 3).  942 
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